Navigation Links
MiMedx Group Raises over $4.9 Million through the Exercise of Callable Warrants
Date:8/6/2012

KENNESAW, Ga., Aug. 6, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company has raised over $4.9 million through the exercise of Callable Warrants issued in conjunction with the October 2010 Private Placement.

The Company exercised its right to redeem the Warrants effective August 3, 2012.  Holders had the option to exercise the Warrants or have them redeemed by the Company.  Over 98% of the Callable Warrants were exercised. 

Parker H. "Pete" Petit, Chairman and CEO, said, "The exercise of these Warrants is a 'win-win' for the Company and our investors, as it strengthens our balance sheet, and provides a nice return for the holders.  The Company intends to use the proceeds for general operating needs, including additional clinical trials, as well as the addition of some key direct sales force hires.  These hires will also help expedite our strategy to expand our direct sales representatives and move  toward a blended sales force."

Cancellation of Second Contingent Warrants

The Company also announced the cancellation of approximately 3.2 million Second Contingent Warrants.  The Warrants had been issued to holders that invested in the Company's October 2010 Private Placement and the Senior Secured Promissory Notes issued in December 2011.  More details regarding the terms of the private placement and warrants are disclosed in the Company's SEC filings.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane.  "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix™, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® Process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant for homologous use. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 90,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to the expected return for the holders of the warrants and the proposed use of proceeds from the exercise of the  warrants.  These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the holders may not realize the expected return on the warrants, that the Company may not employ the proceeds as anticipated, and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2011. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group to Present at the Canaccord Genuity Annual Growth Conference
2. MiMedx Group Announces Record Second Quarter Results
3. MiMedx Group, Inc. Announces Release Date for 2012 Second Quarter Results
4. MiMedx Group Announces Record First Quarter Results
5. MiMedx Exceeds Revenue Goal for First Quarter of 2012
6. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
7. MiMedx Group Announces 2011 Results
8. MiMedx to Present at American Academy of Orthopaedic Surgeons Annual Meeting
9. MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
10. MiMedx Group Completes $5,000,000 Private Placement
11. MiMedx Group, Inc. to Present at the 6th Annual Canaccord Genuity Cardiovascular, Aesthetics and Metabolic Disorders Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... AUSTIN, Texas , Dec. 7, 2016 /PRNewswire/ ... development of revolutionary immunogene therapy treatments, today announced ... healthcare practice within a leading strategic communications and ... strategic communications program. The program will combine investor ... the objective of raising the profile of Genprex ...
(Date:12/7/2016)... DIEGO , December 7, 2016 ... in the International Journal of Molecular Sciences a team of ... 1 ] have demonstrated that expression of NR2F6 ...  These scientists tested for NR2F6 in patient,s cervical cancer tissue ... their tumors. "This is an interesting study and ...
(Date:12/7/2016)... ... December 07, 2016 , ... JULABO USA ... shopping cart. The new website has been designed to provide the best user-friendly ... customers to access detailed product information, read educational industry content as well as ...
(Date:12/6/2016)... 2016 The American Botanical Council (ABC) ... arnica ( Arnica montana ) through ABC,s Adopt-an-Herb ... HerbMedPro database, a comprehensive, interactive online tool ... research data on the uses and health effects ... Naturopathica, a wellness company with healing arts centers, ...
Breaking Biology Technology:
(Date:11/15/2016)... Md. , Nov. 15, 2016  Synthetic ... company developing therapeutics focused on the gut microbiome, ... offering of 25,000,000 shares of its common stock ... common stock at a price to the public ... proceeds to Synthetic Biologics from the offering, excluding ...
(Date:6/27/2016)... DUBLIN , June 27, 2016 Research ... in North America 2016-2020" report to their offering. ... North America to grow at a CAGR ... has been prepared based on an in-depth market analysis with inputs ... growth prospects over the coming years. The report also includes a ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
Breaking Biology News(10 mins):